Cancer Associated Thrombosis and Isoquercetin (CATIQ)
Status:
Completed
Trial end date:
2019-10-22
Target enrollment:
Participant gender:
Summary
This research study is evaluating a drug called isoquercetin to prevent venous thrombosis
(blood clots), in participants who have pancreas, non small cell lung cancer or colorectal
cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Dana-Farber Cancer Institute Jeffrey Zwicker, MD
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) Quercegen Pharmaceuticals